SAC Meeting Calendar

The SAC Tracker Background Analysis is available in this calendar until 10 days after the meeting is held.

 
 

Newest Meeting Announcements

Newest Background Analyses

Featured
Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AAC jessica adams Comment
AUG 3 AAC
Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AAC jessica adams Comment

sNDAs for XELJANZ (tofacitinib) and XELJANZ XR (tofacitinib) by Pfizer for the treatment of adult patients with active psoriatic arthritis

Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AAC jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
JUL 26 AADPAC-DSRM
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment

Intellipharmaceutics Corp.'s, oxycodone hydrochloride extended-release oral tablets

Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment
Meeting Announcement FDA, AADPAC, DSRM jessica adams Comment

Newest Briefing Summaries

Newest Results Wires

Featured
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment
JUL 13 ODAC
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment

Morning session: proposed biosimilar to Genentech/Roche’s AVASTIN (bevacizumab), submitted by Amgen Inc. Afternoon session: a proposed biosimilar to Genentech Inc.’s HERCEPTIN (trastuzumab), submitted by Mylan GmbH.

Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment
JUL 12 ODAC
Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment

Tisagenlecleucel-T suspension by Novartis Pharmaceuticals Corp. for the treatment of pediatric and young adult patients 3 to 25 years of age with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)

Briefing Summary FDA, ODAC jessica adams Comment
Briefing Summary FDA, ODAC jessica adams Comment
Featured
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment
JUL 13 ODAC
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment

Morning session: proposed biosimilar to Genentech/Roche’s AVASTIN (bevacizumab), submitted by Amgen Inc. Afternoon session: a proposed biosimilar to Genentech Inc.’s HERCEPTIN (trastuzumab), submitted by Mylan GmbH.

Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment
JUL 12 ODAC
Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment

Tisagenlecleucel-T suspension by Novartis Pharmaceuticals Corp. for the treatment of pediatric and young adult patients 3 to 25 years of age with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)

Results Wire FDA, ODAC jessica adams Comment
Results Wire FDA, ODAC jessica adams Comment

Search by Tag